Dr. Krampitz on Therapeutic Targets in pNETs
Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
2 Clarke Drive Cranbury, NJ 08512